Summary & Overview
HCPCS Q5137: Ustekinumab-auub (Wezlana), Biosimilar, Subcutaneous 1 mg
HCPCS Level II code Q5137 designates the biosimilar ustekinumab-auub (brand name Wezlana) as a subcutaneous injectable product at a unit strength of 1 mg. This code matters nationally because biologic and biosimilar pricing, access, and coding affect specialty drug spend, prior authorization workflows, and clinician billing practices across payers. As biosimilars enter the market, precise HCPCS coding enables payers, clinicians, and facilities to track utilization, apply appropriate coverage rules, and reconcile pharmacy and medical benefits.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical context, typical sites of service, and the kinds of benchmarks and policy issues that commonly accompany newly coded biosimilars. The publication summarizes expected billing considerations, common modifiers in use, and payer coverage patterns where available. It also highlights policy updates and coding interactions that influence claims processing and reimbursement for subcutaneous biologic therapies. Data not available in the input is noted where applicable; this piece focuses on national implications and operational considerations tied to HCPCS Level II code Q5137.
Billing Code Overview
HCPCS Level II code Q5137 represents an injection of ustekinumab-auub (Wezlana), identified as a biosimilar, delivered subcutaneously at a dosage unit of 1 mg. This code is used to report administration of the biosimilar product itself rather than the clinical visit or separate administration service.
Service Type: Drug administration / Pharmaceutical product
Typical Site of Service: Clinic outpatient setting or physician office; can also be used for infusion centers where subcutaneous biologic therapies are administered.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with moderate to severe plaque psoriasis presents to an outpatient infusion clinic for a subcutaneous biologic injection of ustekinumab-auub (Q5137, wezlana), dosed per weight-based regimen. The patient was previously evaluated by a dermatologist who documented treatment indication, prior therapy failures or contraindications to TNF inhibitors, baseline screening for tuberculosis and hepatitis B/C, and updated immunization status. On the day of service a licensed nurse verifies identity, confirms informed consent and current medications, reviews recent labs and screening results, inspects the intended injection site, and administers the subcutaneous injection. The nurse documents lot number, expiration date, dose (milligrams given), route, site, and any immediate reactions. For payor billing the clinic appends applicable modifier(s) to Q5137 to indicate circumstances such as a partial dose, drug discarded, or medically complex administration. Typical follow-up includes dermatology or rheumatology monitoring visits and periodic laboratory assessment for infections and response to therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological item discarded | Use when part of the vial or prefilled syringe is discarded and the discarded amount is reported per payer policy. |